cp 115953 has been researched along with novobiocin in 3 studies
| Studies (cp 115953) | Trials (cp 115953) | Recent Studies (post-2010) (cp 115953) | Studies (novobiocin) | Trials (novobiocin) | Recent Studies (post-2010) (novobiocin) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 2,271 | 15 | 290 |
| Protein | Taxonomy | cp 115953 (IC50) | novobiocin (IC50) |
|---|---|---|---|
| DNA gyrase subunit B | Mycolicibacterium smegmatis MC2 155 | 0.046 | |
| DNA gyrase subunit B | Staphylococcus aureus | 0.0474 | |
| DNA gyrase subunit B | Streptococcus pneumoniae TIGR4 | 0.037 | |
| DNA gyrase subunit A | Escherichia coli K-12 | 0.1441 | |
| DNA gyrase subunit B | Escherichia coli K-12 | 0.1537 | |
| DNA topoisomerase 4 subunit B | Staphylococcus aureus | 7.9 | |
| DNA gyrase subunit B | Mycolicibacterium smegmatis | 0.161 | |
| DNA gyrase subunit A | Staphylococcus aureus | 0.0383 | |
| DNA gyrase subunit B | Mycobacterium tuberculosis H37Rv | 0.0446 | |
| DNA gyrase subunit A | Mycobacterium tuberculosis H37Rv | 0.1315 | |
| DNA topoisomerase | Streptococcus pneumoniae | 2.03 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forsgren, A; Riesbeck, K | 1 |
| Corbett, AH; Osheroff, N; Robinson, MJ | 1 |
| Corbett, AH; Hong, D; Osheroff, N | 1 |
3 other study(ies) available for cp 115953 and novobiocin
| Article | Year |
|---|---|
CP-115,953 stimulates cytokine production by lymphocytes.
Topics: Anti-Infective Agents; Cells, Cultured; Cytokines; DNA Damage; Etoposide; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-2; Lymphocyte Activation; Novobiocin; Quinolones; RNA, Messenger; T-Lymphocytes; Thymidine; Topoisomerase II Inhibitors | 1995 |
Effects of topoisomerase II-targeted drugs on enzyme-mediated DNA cleavage and ATP hydrolysis: evidence for distinct drug interaction domains on topoisomerase II.
Topics: Adenosine Triphosphate; Amsacrine; Animals; Anti-Infective Agents; Antineoplastic Agents; Binding Sites; Cell Nucleus; DNA Topoisomerases, Type II; DNA, Bacterial; Drosophila melanogaster; Escherichia coli; Etoposide; Fluoroquinolones; Genistein; Hydrolysis; Isoflavones; Novobiocin; Plasmids; Quercetin; Quinolones; Topoisomerase II Inhibitors | 1993 |
Exploiting mechanistic differences between drug classes to define functional drug interaction domains on topoisomerase II. Evidence that several diverse DNA cleavage-enhancing agents share a common site of action on the enzyme.
Topics: Amsacrine; Animals; Anti-Infective Agents; Binding Sites; Cell Line; Cell Nucleus; DNA; DNA Topoisomerases, Type II; DNA, Superhelical; Drosophila melanogaster; Drug Interactions; Etoposide; Fluoroquinolones; Genistein; Growth Inhibitors; Isoflavones; Kinetics; Novobiocin; Protein Binding; Quinolones; Structure-Activity Relationship; Topoisomerase II Inhibitors | 1993 |